CR10680A - Composiciones de inhibidores de chk1 - Google Patents
Composiciones de inhibidores de chk1Info
- Publication number
- CR10680A CR10680A CR10680A CR10680A CR10680A CR 10680 A CR10680 A CR 10680A CR 10680 A CR10680 A CR 10680A CR 10680 A CR10680 A CR 10680A CR 10680 A CR10680 A CR 10680A
- Authority
- CR
- Costa Rica
- Prior art keywords
- chk1 inhibitors
- inhibitors compositions
- compositions
- cyclodextrin
- chk1
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
La presente invencion se refiere a composiciones que contienen al menos, un inhibidor de Chk1 y al menos una ciclodextrina. Tambien se describen metodos para tratar un cancer o potenciar un tratamiento de cancer con una composicion que comprende al menos, un inhibidor de Chk1 y al menos una ciclodextrina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85305606P | 2006-10-20 | 2006-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10680A true CR10680A (es) | 2009-10-13 |
Family
ID=39338658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10680A CR10680A (es) | 2006-10-20 | 2009-03-20 | Composiciones de inhibidores de chk1 |
Country Status (22)
Country | Link |
---|---|
US (1) | US8455471B2 (es) |
EP (1) | EP2063879A2 (es) |
JP (1) | JP2010506942A (es) |
KR (2) | KR20110098009A (es) |
CN (1) | CN101528215B (es) |
AU (1) | AU2007325576B2 (es) |
BR (1) | BRPI0717460A2 (es) |
CA (1) | CA2673483C (es) |
CO (1) | CO6180503A2 (es) |
CR (1) | CR10680A (es) |
EA (1) | EA200900571A1 (es) |
IL (1) | IL197869A (es) |
MA (1) | MA30872B1 (es) |
MX (1) | MX2009004214A (es) |
MY (1) | MY150649A (es) |
NO (1) | NO20091544L (es) |
NZ (1) | NZ575394A (es) |
SV (1) | SV2009003227A (es) |
TN (1) | TN2009000146A1 (es) |
UA (1) | UA95310C2 (es) |
WO (1) | WO2008067027A2 (es) |
ZA (1) | ZA200902670B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI1012301A2 (pt) | 2009-05-29 | 2015-09-22 | Cydex Pharmaceuticals Inc | composições de melfalano injetáveis compreendendo um derivado de ciclodextrina e métodos de preparar e usar o mesmo |
US11020363B2 (en) | 2009-05-29 | 2021-06-01 | Cydex Pharmaceuticals, Inc. | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
GB201008005D0 (en) * | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
MX346432B (es) * | 2011-09-18 | 2017-03-21 | Euro-Celtique S A * | Composiciones farmaceuticas. |
EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
PT2763984T (pt) | 2011-10-03 | 2016-07-25 | Respivert Ltd | 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il) ureias como inibidores da map cinase p38 |
TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
CN104244956B (zh) * | 2012-04-13 | 2020-04-17 | L&F研究有限公司 | 使用环糊精的方法 |
WO2015013581A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
TWI751099B (zh) | 2014-02-14 | 2022-01-01 | 英商瑞斯比維特有限公司 | 作為激酶抑制劑之吡唑基脲,包含其之製藥組成物及其用途 |
GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
US9890564B2 (en) | 2014-10-28 | 2018-02-13 | Sargent Manufacturing Company | Interconnected lock with direct drive for adjustable deadbolt to latchbolt spacing |
JP2017155023A (ja) * | 2016-03-04 | 2017-09-07 | ジェイファーマ株式会社 | Lat1阻害活性を有する芳香族アミノ酸誘導体を含有する注射剤 |
EP3432880A4 (en) * | 2016-03-20 | 2019-12-11 | Asdera LLC | USE OF CYCLODEXTRINS TO REDUCE ENDOCYTOSIS IN MALIGNANT AND NEURODEGENERATIVE DISORDERS |
WO2018068832A1 (en) | 2016-10-11 | 2018-04-19 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
KR20200107927A (ko) | 2017-09-28 | 2020-09-16 | 아스데라 엘엘씨 | 인지질 조절장애를 수반하는 질환 및 장애에서의 시클로덱스트린의 용도 |
CN109078005B (zh) * | 2018-08-07 | 2021-11-26 | 江苏领航生物科技有限公司 | 一种白消安组合物及其制备方法和应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
HU193933B (en) | 1984-06-08 | 1987-12-28 | Nitrokemia Ipartelepek | Herbicide or plant growth stimulating agent comprising beta-cyclodextrin complex of benzolsulphonylurea derivative and process for preparing the active substances |
IE62095B1 (en) * | 1988-03-29 | 1994-12-14 | Univ Florida | Pharmaceutical formulations for parenteral use |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9001987D0 (en) | 1990-01-29 | 1990-03-28 | Janssen Pharmaceutica Nv | Improved cyclodextrin based erythropietin formulation |
US5602112A (en) | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
EP1067942A1 (en) * | 1998-02-23 | 2001-01-17 | Cyclops, EHF. | High-energy cyclodextrin complexes |
US6565880B2 (en) * | 2000-07-24 | 2003-05-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea |
UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
CA2454913A1 (en) | 2001-08-20 | 2003-02-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-¬4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl|-urea and a cyclodextrin |
SE0201658D0 (sv) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Immediate release pharmaceutical formulation |
CA2539320A1 (en) * | 2003-09-17 | 2005-03-31 | Icos Corporation | Use of chk1 inhibitors to control cell proliferation |
KR20050039573A (ko) * | 2003-10-23 | 2005-04-29 | 주식회사 태평양 | 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물 |
EP1869020B1 (en) * | 2005-03-29 | 2010-12-01 | ICOS Corporation | Heteroaryl urea derivatives useful for inhibiting chk1 |
CN1813739A (zh) | 2005-11-25 | 2006-08-09 | 王颖 | 一种注射用盐酸纳美芬冻干粉针制剂 |
-
2007
- 2007-10-02 US US12/442,529 patent/US8455471B2/en not_active Expired - Fee Related
- 2007-10-02 KR KR1020117017995A patent/KR20110098009A/ko not_active Application Discontinuation
- 2007-10-02 NZ NZ575394A patent/NZ575394A/en not_active IP Right Cessation
- 2007-10-02 KR KR1020097007975A patent/KR20090065537A/ko not_active Application Discontinuation
- 2007-10-02 MX MX2009004214A patent/MX2009004214A/es active IP Right Grant
- 2007-10-02 UA UAA200903745A patent/UA95310C2/ru unknown
- 2007-10-02 EP EP07871106A patent/EP2063879A2/en not_active Withdrawn
- 2007-10-02 MY MYPI20091558 patent/MY150649A/en unknown
- 2007-10-02 CN CN2007800390301A patent/CN101528215B/zh not_active Expired - Fee Related
- 2007-10-02 BR BRPI0717460-8A2A patent/BRPI0717460A2/pt not_active IP Right Cessation
- 2007-10-02 CA CA2673483A patent/CA2673483C/en not_active Expired - Fee Related
- 2007-10-02 JP JP2009533425A patent/JP2010506942A/ja active Pending
- 2007-10-02 WO PCT/US2007/080150 patent/WO2008067027A2/en active Application Filing
- 2007-10-02 AU AU2007325576A patent/AU2007325576B2/en not_active Ceased
- 2007-10-02 EA EA200900571A patent/EA200900571A1/ru unknown
-
2009
- 2009-03-20 CR CR10680A patent/CR10680A/es unknown
- 2009-03-26 IL IL197869A patent/IL197869A/en not_active IP Right Cessation
- 2009-04-17 CO CO09039148A patent/CO6180503A2/es not_active Application Discontinuation
- 2009-04-17 TN TNP2009000146A patent/TN2009000146A1/fr unknown
- 2009-04-17 ZA ZA200902670A patent/ZA200902670B/xx unknown
- 2009-04-20 SV SV2009003227A patent/SV2009003227A/es unknown
- 2009-04-20 NO NO20091544A patent/NO20091544L/no not_active Application Discontinuation
- 2009-05-07 MA MA31850A patent/MA30872B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
MY150649A (en) | 2014-02-14 |
CA2673483A1 (en) | 2008-06-05 |
MA30872B1 (fr) | 2009-11-02 |
CO6180503A2 (es) | 2010-07-19 |
CA2673483C (en) | 2014-04-08 |
IL197869A0 (en) | 2009-12-24 |
BRPI0717460A2 (pt) | 2013-12-24 |
CN101528215B (zh) | 2011-10-19 |
SV2009003227A (es) | 2010-02-04 |
EA200900571A1 (ru) | 2009-12-30 |
WO2008067027A2 (en) | 2008-06-05 |
IL197869A (en) | 2013-11-28 |
KR20090065537A (ko) | 2009-06-22 |
MX2009004214A (es) | 2009-05-11 |
US20100022512A1 (en) | 2010-01-28 |
NZ575394A (en) | 2012-01-12 |
US8455471B2 (en) | 2013-06-04 |
UA95310C2 (ru) | 2011-07-25 |
KR20110098009A (ko) | 2011-08-31 |
CN101528215A (zh) | 2009-09-09 |
AU2007325576B2 (en) | 2013-01-10 |
NO20091544L (no) | 2009-06-10 |
EP2063879A2 (en) | 2009-06-03 |
ZA200902670B (en) | 2010-06-30 |
TN2009000146A1 (en) | 2010-10-18 |
AU2007325576A1 (en) | 2008-06-05 |
WO2008067027A3 (en) | 2009-04-16 |
JP2010506942A (ja) | 2010-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10680A (es) | Composiciones de inhibidores de chk1 | |
TW200738263A (en) | ANG2 and VEGF inhibitor combinations | |
ECSP099634A (es) | Derivados de piridazinona útiles como inhibidores de glucano sintasa | |
HN2009001112A (es) | Inhibidores de la actividad de la akt | |
CO6321188A2 (es) | Tratamiento de cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de parp | |
EA200900819A1 (ru) | Хиназолины для ингибирования pdk1 | |
MX2009009761A (es) | Composiciones y estuches para tratamiento de la influenza. | |
CR11299A (es) | Amidas heterociclicas utiles para el tratamiento de cancer y psoriasis | |
GT200800151A (es) | Inhibidores de 11-beta-hsd1 | |
SG169988A1 (en) | Rnai inhibition of alpha-enac expression | |
CR10277A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
CL2008003653A1 (es) | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. | |
ECSP099398A (es) | Compuestos y métodos para inhibir la interacción de las proteínas bcl con agentes aglutinantes | |
NO20080785L (no) | Behandling av kreft | |
CR20120115A (es) | Terapia de combinacion con composiciones de nanoparticulas de taxano e inhibidores de hedgehog | |
CO6331446A2 (es) | Composiciones farmaceúticas que comprenden la combinación de un agente antimitotico y un compuesto inhibidor de aurora quinasa, utiles en el tratamiento anticancerígeno | |
CL2011000957A1 (es) | Compuesto derivados de isoindolina sustituidos, inhibidores de citosinas tnf-a; composicion farmaceutica; utiles en el tratamiento del cancer. | |
UY31789A1 (es) | Composiciones de insulina de super rápida actuación | |
EA200870415A1 (ru) | Хиназолины для ингибирования pdk 1 | |
BRPI0712607A8 (pt) | métodos de tratamento de acidente vascular cerebral | |
TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
ATE510822T1 (de) | Kaliumkanalinhibitoren | |
ATE531721T1 (de) | Cyanoaminochinolone als gsk-3-inhibitoren | |
MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
BRPI0603772A (pt) | composições para a inibição ou redução de inflamação da pele |